1. A phase II multi-center trial of pentostatin plus cyclophosphamide with ofatumumab in older previously untreated chronic lymphocytic leukemia patients
- Author
-
Ester Orlandi, Marco Montillo, Marianna Rossi, Lydia Scarfò, Giulia Quaresmini, Gianluca Gaidano, Agostino Cortelezzi, Guido Nador, Antonella Anastasia, Lorenzo De Paoli, Davide Rossi, Marina Motta, Daniela Dalceggio, Anna Maria Frustaci, Fausto Rossini, Marta Coscia, Massimo Massaia, Alessandro Rambaldi, Alessandra Tedeschi, Roberto Cairoli, Paola Picardi, Tedeschi, A, Rossi, D, Motta, M, Quaresmini, G, Rossi, M, Coscia, M, Anastasia, A, Rossini, F, Cortelezzi, A, Nador, G, Scarfo, L, Cairoli, R, Frustaci, A, Dalceggio, D, Picardi, P, de Paoli, L, Orlandi, E, Rambaldi, A, Massaia, M, Gaidano, G, and Montillo, M
- Subjects
Oncology ,medicine.medical_specialty ,Chronic lymphocytic leukemia, Cyclophosphamide, Elderly, Ofatumumab, Pentostatin, Hematology ,Cyclophosphamide ,Chronic lymphocytic leukemia ,Ofatumumab ,chemistry.chemical_compound ,Elderly ,immune system diseases ,hemic and lymphatic diseases ,Internal medicine ,medicine ,Pentostatin ,Online Only Articles ,business.industry ,Hematology ,medicine.disease ,Fludarabine ,Leukemia ,chemistry ,Immunology ,Rituximab ,business ,Untreated Chronic Lymphocytic Leukemia ,medicine.drug - Abstract
There is a significant need to develop an efficient treatment, without sacrificing efficacy, for older fit patients with chronic lymphocytic leukemia (CLL) as fludarabine, cyclophosphamide and rituximab (FCR) have very often led to treatment-related toxicities, causing delay or therapy
- Published
- 2015